Literature DB >> 10586933

Failure to activate transcription factor NF-kappaB in corneal stromal cells (keratocytes).

J R Cook1, M K Mody, M E Fini.   

Abstract

PURPOSE: Freshly isolated cultures of corneal stromal cells (keratocytes) are incompetent to synthesize the tissue remodeling proteinase, collagenase, in response to agents such as cytochalasin B (CB) or phorbol myristate acetate (PMA), which are strong stimulators of collagenase expression in subcultured fibroblasts of all types, including those from corneal stroma. Incompetence is due to failure to activate an autocrine interleukin (IL)1alpha feedback loop required to mediate cell response. The goal of the present study was to investigate the mechanism for this failure.
METHODS: A cell culture model of freshly isolated corneal stromal cells and subcultured stromal fibroblasts from rabbits was used for these studies.
RESULTS: Competence to synthesize collagenase in response to CB was acquired as a differentiation property by corneal stromal cells placed in culture, and did not require subculture. Competence acquisition correlated with transition to a fibroblastic spindle shape, assembly of actin stress fibers, and the acquired capacity to collapse in response to CB. It was demonstrated that competence could be more precisely defined as the capacity to express IL-1alpha in response to IL-1, making possible activation of the feedback loop. Investigation into the signaling pathway for IL-1alpha expression in response to IL-1 revealed a requirement for reactive oxygen species and activity of the transcription factor nuclear factor (NF)kappaB. Importantly, freshly isolated stromal cells were found to be relatively incompetent to activate NF-kappaB in comparison to subcultured stromal fibroblasts.
CONCLUSIONS: Failure to activate NF-kappaB explains incompetence for expression of IL-1alpha in corneal stromal cells. Because NF-kappaB regulates many cell functions with potential to disturb corneal structure, including expression of inflammatory, stress, and degradative proteinase genes; protection against apoptosis; and cell replication; this seems likely to be an important mechanism protecting corneal stasis and preserving function.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10586933

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  6 in total

1.  Activation of a tissue-specific stress response in the aqueous outflow pathway of the eye defines the glaucoma disease phenotype.

Authors:  N Wang; S K Chintala; M E Fini; J S Schuman
Journal:  Nat Med       Date:  2001-03       Impact factor: 53.440

2.  Corneal antifibrotic switch identified in genetic and pharmacological deficiency of vimentin.

Authors:  Paola Bargagna-Mohan; Riya R Paranthan; Adel Hamza; Chang-Guo Zhan; Do-Min Lee; Kyung Bo Kim; Daniel L Lau; Cidambi Srinivasan; Keiko Nakayama; Keiichi I Nakayama; Harald Herrmann; Royce Mohan
Journal:  J Biol Chem       Date:  2011-11-22       Impact factor: 5.157

3.  Keratocyte phenotype mediates proteoglycan structure: a role for fibroblasts in corneal fibrosis.

Authors:  James L Funderburgh; Mary M Mann; Martha L Funderburgh
Journal:  J Biol Chem       Date:  2003-08-20       Impact factor: 5.157

4.  Mechanisms for PDGF, a serum cytokine, stimulating loss of corneal keratocyte crystallins.

Authors:  Adriana J LaGier; Gabriel M Gordon; Lee R Katzman; Vasilis Vasiliou; M Elizabeth Fini
Journal:  Cornea       Date:  2013-09       Impact factor: 2.651

5.  Differential expression of epithelial basement membrane components nidogens and perlecan in corneal stromal cells in vitro.

Authors:  Abirami Santhanam; Andre A M Torricelli; Jiahui Wu; Gustavo K Marino; Steven E Wilson
Journal:  Mol Vis       Date:  2015-12-29       Impact factor: 2.367

6.  Antifibrotic effect by activation of peroxisome proliferator-activated receptor-gamma in corneal fibroblasts.

Authors:  Hongwei Pan; Jiansu Chen; Jintang Xu; Miaojiao Chen; Rong Ma
Journal:  Mol Vis       Date:  2009-11-10       Impact factor: 2.367

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.